First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.
about
Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysisIncreasing off-label use of antipsychotic medications in the United States, 1995-2008Schizophrenia: a multisystem disease?Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesClinical utility of the risperidone formulations in the management of schizophrenia.Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data.Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activityAre there modifiable risk factors which will reduce the excess mortality in schizophrenia?Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patientsElderly patients with schizophrenia and depression: diagnosis and treatmentDiabetes and cognitive deficits in chronic schizophrenia: a case-control study.Metabolome in schizophrenia and other psychotic disorders: a general population-based study.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Pharmacologic treatment of first-episode schizophrenia: a review of the literatureRelationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medicationsEffect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's DiseaseAtypical antipsychotic initiation and the risk of type II diabetes in children and adolescents.Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia.Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven reviewCost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Ethnicity and cardiovascular health inequalities in people with severe mental illnesses: protocol for the E-CHASM studyPolygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Misclassification in assessment of diabetogenic risk using electronic health records.Development of diabetes mellitus associated with quetiapine: A case series.Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis.Antipsychotics activate the TGFβ pathway effector SMAD3Using Routine Hemoglobin A1c Testing to Determine the Glycemic Status in Psychiatric Inpatients.Peer navigators and integrated care to address ethnic health disparities of people with serious mental illnessEfficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.
P2860
Q24603049-D6306C27-8724-4E9D-B061-51546A0CA258Q24628874-846946A7-E197-45BE-A284-28ED85208011Q24633845-ABEFEF97-7F43-46FD-9138-CB99A6471D39Q26863435-0D8F3247-5671-441D-82B0-4DF7F02E759AQ30429721-D58B040C-DB5D-4851-ADF5-5E5592CE5712Q30650589-87FC578D-6E52-4415-AE4F-679031B07A50Q33371995-B5190A53-4FD4-4CC4-925D-D45C4F829511Q33890480-33D7BE9F-B174-47B6-A785-8FC4C325FC7DQ33915509-E799C074-CBA7-4F76-99B3-3468FE3E2309Q34101256-F628885B-D4AD-4D1C-8954-2B483B23195BQ34183495-B9515155-56C4-4B2E-AB2C-3A0374CCA332Q34386877-555C637C-6E66-4117-B4A0-31E2ABA17646Q34491836-0291C954-E080-40A7-8BF3-0E6FF64833B0Q34623350-9C39A5D0-5ABC-4758-A309-98A4E9B61637Q34631699-44B094F6-8301-43B3-9427-657BB2A8C7BCQ34640811-192527D7-65CD-4965-A81D-BE1B50691B47Q34661651-141BD221-CD80-489D-9CB4-82A2B7CC2226Q34707472-1C7F2C09-6CE4-4C69-BAC5-F741C0ABFA64Q34805258-CB19A5E2-0A45-4812-B075-19A6CA6751B7Q34971495-A99E1B49-5C05-470B-A2E6-EB43DFC41E60Q35754726-1FEAE426-7644-484E-897B-16F970A195C4Q35977796-C6AF05E6-80B7-449A-B687-BC5EF20C6C17Q36061357-AEAD9DC7-4387-4487-8A23-A0F2FFA46B8FQ36194233-54D8E1DB-C0B2-4A01-9BD0-CA34031BF21FQ36270899-063C996C-EE04-4B96-A3F2-A5DF229A85FBQ36555343-3AA0AFFA-BA15-483D-9FE9-13C7BC27A351Q36593819-F4AE9CEF-76D9-4EFA-8527-FDAEFDD0F37BQ36600817-E1C24613-D19F-494D-87E7-B24DEBF24A3DQ36698856-431D2DBE-3166-4108-A174-ECABDE1B9F22Q36772796-E69335C6-84CB-491D-A798-4BB4151FDBCAQ36784390-8E711819-6A32-4708-A8BE-4AC70CD55587Q37079080-31B84A8B-B7F9-4A0D-8EAA-9E7469D1AE35Q37233836-AB037746-D01B-4307-8E27-55EEBA103FD4Q37613388-79036093-2B79-4886-9E4F-FE2EB46D22E0Q37635208-B87D4A05-B3AA-4FEE-99F7-2B692795166EQ37710090-FA91A831-D199-4811-9964-7A0A6A993950Q37721692-16C61FCC-F329-4B32-9472-2B7FDBA7FBF5Q37727108-1368699F-2318-48B3-B55E-EEA5D1D140E3Q37737291-C20B0A7E-3101-4809-8FC9-341BFC807F8CQ37914103-658C5CE6-9020-46F8-9C15-CA1EBBACDF56
P2860
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
First- v. second-generation an ...... atic review and meta-analysis.
@en
First- v. second-generation an ...... atic review and meta-analysis.
@nl
type
label
First- v. second-generation an ...... atic review and meta-analysis.
@en
First- v. second-generation an ...... atic review and meta-analysis.
@nl
prefLabel
First- v. second-generation an ...... atic review and meta-analysis.
@en
First- v. second-generation an ...... atic review and meta-analysis.
@nl
P2093
P1476
First- v. second-generation an ...... atic review and meta-analysis.
@en
P2093
P304
P356
10.1192/BJP.BP.107.037184
P407
P577
2008-06-01T00:00:00Z